Changes in Subjective Cognitive and Social Functioning in Parkinson’s Disease from Before to During the COVID-19 Pandemic
Abstract
:1. Introduction
2. Materials and Methods
2.1. Participants
2.2. Measures
- Social Roles and Activities (Neuro-QoLsocial): This is an 8-item scale that measures an individual’s degree of involvement in social roles, activities, and responsibilities, including work, family, friends and leisure. Total scores range from 8 to 40, with higher scores indicating better performance.
- Cognitive Function (Neuro-QoLcog): This is an 8-item scale that measures an individual’s self-reported difficulties in various cognitive abilities and their application, including memory, attention, decision making, planning, organization, calculating, remembering, and learning. Total scores range from 8 to 40, with higher scores indicating better performance.
- Positive Affect and Well-Being (Neuro-QoLwell-being): This is a 9-item scale that measures individual’s sense of well-being, life-satisfaction, and an overall sense of purpose and meaning. Total scores range from 9 to 45, with higher scores indicating better performance.
- Fatigue (Neuro-QoLfatigue): This is an 8-item scale that measures degree of fatigue ranging from tiredness to an overwhelming and sustained sense of exhaustion. Total scores of this scale range from 8 to 40, with higher scores indicating greater fatigue.
- Part I—Non-Motor Aspects of Experiences of Daily Living (UPDRSnon-motor): This is a 7-item self-report questionnaire that measures various non-motor aspects of PD including sleep problems, daytime sleepiness, pain, urinary problems, constipation, lightheadedness, and fatigue. Total UPDRSnon-motor scores can range from 0 to 28, with higher scores indicating more severe symptoms.
- Part II—Motor Aspects of Experiences of Daily Living (UPDRSmotor): This is a 13-item self-report questionnaire on motor-symptoms, including problems with speech, drooling, swallowing, eating, dressing, hygiene management, handwriting, engaging in hobbies and other activities, turning in bed, tremor, getting out of a bed, car or chair, walking and balance, and freezing of gait. Total UPDRSmotor scores can range from 0 to 52, with higher scores indicating more severe symptoms.
2.3. Statistical Analyses
3. Results
3.1. Whole Sample
3.2. Gender-Wise Analyis
4. Discussion
Limitations
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Moustafa, A.A.; Chakravarthy, S.; Phillips, J.R.; Gupta, A.; Keri, S.; Polner, B.; Frank, M.J.; Jahanshahi, M. Motor symptoms in Parkinson’s disease: A unified framework. Neurosci. Biobehav. Rev. 2016, 68, 727–740. [Google Scholar] [CrossRef] [PubMed]
- Chaudhuri, K.R.; Schapira, A.H.V. Non-motor symptoms of Parkinson’s disease: Dopaminergic pathophysiology and treatment. Lancet. Neurol. 2009, 8, 464–474. [Google Scholar] [CrossRef] [PubMed]
- Zesiewicz, T.A.; Sullivan, K.L.; Arnulf, I.; Chaudhuri, K.R.; Morgan, J.C.; Gronseth, G.S.; Miyasaki, J.; Iverson, D.J.; Weiner, W.J.; Quality Standards Subcommittee of the American Academy of Neurology. Practice Parameter: Treatment of nonmotor symptoms of Parkinson disease: Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2010, 74, 924–931. [Google Scholar] [CrossRef] [PubMed]
- Schrag, A.; Jahanshahi, M.; Quinn, N. What contributes to quality of life in patients with Parkinson’s disease? J. Neurol. Neurosurg. Psychiatry 2000, 69, 308–312. [Google Scholar] [CrossRef]
- Subramanian, I.; Farahnik, J.; Mischley, L.K. Synergy of pandemics-social isolation is associated with worsened Parkinson severity and quality of life. npj Park. Dis. 2020, 6, 28. [Google Scholar] [CrossRef]
- Maffoni, M.; Giardini, A.; Pierobon, A.; Ferrazzoli, D.; Frazzitta, G. Stigma experienced by Parkinson’s disease patients: A descriptive review of qualitative studies. Park. Dis. 2017, 2017, 7203259. [Google Scholar] [CrossRef]
- Salazar, R.D.; Weizenbaum, E.; Ellis, T.D.; Earhart, G.M.; Ford, M.P.; Dibble, L.E.; CroninGolomb, A. Predictors of self-perceived stigma in Parkinson’s disease. Park. Relat. Disord. 2019, 60, 76–80. [Google Scholar] [CrossRef]
- Islam, S.S.; Neargarder, S.; Kinger, S.B.; Fox-Fuller, J.T.; Salazar, R.D.; Cronin-Golomb, A. Perceived stigma and quality of life in Parkinson’s disease with additional health conditions. Gen. Psychiatry 2022, 35, e100653. [Google Scholar] [CrossRef]
- Logan, B.A.; Neargarder, S.; Kinger, S.B.; Larum, A.K.; Salazar, R.D.; Cronin-Golomb, A. Self-perceived stigma in Parkinson’s disease in an online sample: Comparison with in-person sample, role of anxiety, and relative utility of four measures of stigma perception. Appl. Neuropsychol. Adult 2024, 1–10. [Google Scholar] [CrossRef]
- Soleimani, M.A.; Negarandeh, R.; Bastani, F.; Greysen, R. Disrupted social connectedness in people with Parkinson’s disease. Br. J. Community Nurs. 2014, 19, 136–141. [Google Scholar] [CrossRef]
- Sjödahl Hammarlund, C.; Westergren, A.; Åström, I.; Edberg, A.-K.; Hagell, P. The impact of living with Parkinson’s disease: Balancing within a web of needs and demands. Park. Dis. 2018, 2018, 4598651. [Google Scholar] [CrossRef] [PubMed]
- Ma, H.-I.; Gunnery, S.D.; Stevenson, M.T.; Saint-Hilaire, M.; Thomas, C.A.; Tickle-Degnen, L. Experienced facial masking indirectly compromises quality of life through stigmatization of women and men with Parkinson’s disease. Stigma Health 2019, 4, 462–472. [Google Scholar] [CrossRef] [PubMed]
- Kinger, S.B.; Moran, J.; McLarin, A.; Fox-Fuller, J.T.; Salazar, R.D.; Gordillo, M.L.; Long, K.A.; Cronin-Golomb, A. We hope you’re listening: Qualitative study of advice given by individuals with Parkinson’s disease. Mov. Disord. Clin. Pract. 2024, 11, 1427–1433. [Google Scholar] [CrossRef] [PubMed]
- Sayin Kasar, K.; Karaman, E. Life in lockdown: Social isolation, loneliness and quality of life in the elderly during the COVID-19 pandemic: A scoping review. Geriatr. Nurs. 2021, 42, 1222–1229. [Google Scholar] [CrossRef]
- Ingram, J.; Hand, C.J.; Maciejewski, G. Social isolation during COVID-19 lockdown impairs cognitive function. Appl. Cogn. Psychol. 2021, 35, 935–947. [Google Scholar] [CrossRef]
- Shankar, A.; Hamer, M.; McMunn, A.; Steptoe, A. Social isolation and loneliness: Relationships with cognitive function during 4 years of follow-up in the English Longitudinal Study of Ageing. Psychosom. Med. 2013, 75, 161–170. [Google Scholar] [CrossRef]
- Santini, Z.I.; Jose, P.E.; York Cornwell, E.; Koyanagi, A.; Nielsen, L.; Hinrichsen, C.; Meilstrup, C.; Madsen, K.R.; Koushede, V. Social disconnectedness, perceived isolation, and symptoms of depression and anxiety among older Americans (NSHAP): A longitudinal mediation analysis. Lancet Public Health 2020, 5, e62–e70. [Google Scholar] [CrossRef]
- Evans, I.E.M.; Martyr, A.; Collins, R.; Brayne, C.; Clare, L. Social isolation and cognitive function in later life: A systematic review and meta-analysis. J. Alzheimer’s Dis. JAD 2019, 70 (Suppl. S1), S119–S144. [Google Scholar] [CrossRef]
- Gow, A.J.; Avlund, K.; Mortensen, E.L. Occupational characteristics and cognitive aging in the Glostrup 1914 Cohort. J. Gerontol. Ser. B Psychol. Sci. Soc. Sci. 2014, 69, 228–236. [Google Scholar] [CrossRef]
- Kuiper, J.S.; Zuidersma, M.; Zuidema, S.U.; Burgerhof, J.G.; Stolk, R.P.; Oude Voshaar, R.C.; Smidt, N. Social relationships and cognitive decline: A systematic review and meta-analysis of longitudinal cohort studies. Int. J. Epidemiol. 2016, 45, 1169–1206. [Google Scholar] [CrossRef]
- Tilvis, R.S.; Kähönen-Väre, M.H.; Jolkkonen, J.; Valvanne, J.; Pitkala, K.H.; Strandberg, T.E. Predictors of cognitive decline and mortality of aged people over a 10-year period. J. Gerontol. Ser. A Biol. Sci. Med. Sci. 2004, 59, 268–274. [Google Scholar] [CrossRef] [PubMed]
- Wilson, R.S.; Krueger, K.R.; Arnold, S.E.; Schneider, J.A.; Kelly, J.F.; Barnes, L.L.; Tang, Y.; Bennett, D.A. Loneliness and risk of Alzheimer disease. Arch. Gen. Psychiatry 2007, 64, 234–240. [Google Scholar] [CrossRef] [PubMed]
- Kolakowsky-Hayner, S.A.; Goldin, Y.; Kingsley, K.; Alzueta, E.; Arango-Lasprilla, J.C.; Perrin, P.B.; Baker, F.C.; Ramos-Usuga, D.; Constantinidou, F. Psychosocial impacts of the COVID-19 quarantine: A study of gender differences in 59 countries. Medicina 2021, 57, 789. [Google Scholar] [CrossRef]
- Miller, I.N.; Cronin-Golomb, A. Gender differences in Parkinson’s disease: Clinical characteristics and cognition. Mov. Disord. Off. J. Mov. Disord. Soc. 2010, 25, 2695–2703. [Google Scholar] [CrossRef]
- Reekes, T.H.; Higginson, C.I.; Ledbetter, C.R.; Sathivadivel, N.; Zweig, R.M.; Disbrow, E.A. Sex specific cognitive differences in Parkinson disease. npj Park. Dis. 2020, 6, 7. [Google Scholar] [CrossRef]
- Kinger, S.B.; Juneau, T.; Kaplan, R.I.; Pluim, C.F.; Fox-Fuller, J.T.; Wang, T.; Mukadam, N.; Neargarder, S.; Salazar, R.D.; Cronin-Golomb, A. Changes in apathy, depression, and anxiety in Parkinson’s disease from before to during the COVID-19 era. Brain Sci. 2023, 13, 199. [Google Scholar] [CrossRef]
- Stoddard, J.; Reynolds, E.K.; Paris, R.; Haller, S.; Johnson, S.; Zik, J.; Elliotte, E.; Maru, M.; Jaffe, A.; Mallidi, A.; et al. The Coronavirus Impact Scale: Construction, Validation, and Comparisons in Diverse Clinical Samples. PsyArXiv 2021, preprints. [Google Scholar] [CrossRef]
- Cella, D.; Lai, J.-S.; Nowinski, C.J.; Victorson, D.; Peterman, A.; Miller, D.; Bethoux, F.; Heinemann, A.; Rubin, S.; Cavazos, J.E.; et al. Neuro-QOL. Neurology 2012, 78, 1860–1867. [Google Scholar] [CrossRef]
- Goetz, C.G.; Fahn, S.; Martinez-Martin, P.; Poewe, W.; Sampaio, C.; Stebbins, G.T.; Stern, M.B.; Tilley, B.C.; Dodel, R.; Dubois, B.; et al. Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov. Disord. Off. J. Mov. Disord. Soc. 2007, 22, 41–47. [Google Scholar] [CrossRef]
- Beck, A.T. Manual for the Beck Depression Inventory-II; Psychological Corporation: San Antonio, TX, USA, 1996. [Google Scholar]
- Leentjens, A.F.G.; Dujardin, K.; Pontone, G.M.; Starkstein, S.E.; Weintraub, D.; Martinez-Martin, P. The Parkinson Anxiety Scale (PAS): Development and validation of a new anxiety scale. Mov. Disord. Off. J. Mov. Disord. Soc. 2014, 29, 1035–1043. [Google Scholar] [CrossRef]
- Marras, C.; Mills, K.A.; Eberly, S.; Oakes, D.; Chou, K.L.; Halverson, M.; Parashos, S.A.; Tarolli, C.G.; Lai, J.-S.; Nowinsky, C.J.; et al. Longitudinal change in Neuro-QoL measures over 3 years in patients with early Parkinson’s disease. Mov. Disord. Off. J. Mov. Disord. Soc. 2021, 36, 1979–1983. [Google Scholar] [CrossRef] [PubMed]
- Hawkins, R.B.; Charles, E.J.; Mehaffey, J.H. Socio-economic status and COVID-19-related cases and fatalities. Public Health 2020, 189, 129–134. [Google Scholar] [CrossRef] [PubMed]
- Feeney, M.P.; Xu, Y.; Surface, M.; Shah, H.; Vanegas-Arroyave, N.; Chan, A.K.; Delaney, E.; Przedborski, S.; Beck, J.C.; Alcalay, R.N. The impact of COVID-19 and social distancing on people with Parkinson’s disease: A survey study. npj Park. Dis. 2021, 7, 10. [Google Scholar] [CrossRef]
- Erro, R.; Picillo, M.; Vitale, C.; Amboni, M.; Moccia, M.; Santangelo, G.; Pellecchia, M.T.; Barone, P. The non-motor side of the honeymoon period of Parkinson’s disease and its relationship with quality of life: A 4-year longitudinal study. Eur. J. Neurol. 2016, 23, 1673–1679. [Google Scholar] [CrossRef] [PubMed]
- Ou, R.; Hou, Y.; Wei, Q.; Lin, J.; Liu, K.; Zhang, L.; Jiang, Z.; Cao, B.; Zhao, B.; Song, W.; et al. Longitudinal evolution of non-motor symptoms in early Parkinson’s disease: A 3-year prospective cohort study. npj Park. Dis. 2021, 7, 58. [Google Scholar] [CrossRef] [PubMed]
- Amieva, H.; Retuerto, N.; Hernandez-Ruiz, V.; Meillon, C.; Dartigues, J.-F.; Pérès, K. Longitudinal study of cognitive decline before and after the COVID-19 pandemic: Evidence from the PA-COVID survey. Dement. Geriatr. Cogn. Disord. 2022, 51, 56–62. [Google Scholar] [CrossRef]
- Cadar, D. The impact of the COVID-19 pandemic on cognitive decline. Lancet Healthy Longev. 2023, 4, e585–e586. [Google Scholar] [CrossRef]
- Palermo, G.; Tommasini, L.; Baldacci, F.; Del Prete, E.; Siciliano, G.; Ceravolo, R. Impact of Coronavirus Disease 2019 pandemic on cognition in Parkinson’s disease. Mov. Disord. 2020, 35, 1717–1718. [Google Scholar] [CrossRef]
- Barbosa, R.P.; Mendonça, M.D.; Caetano, A.P.; Lampreia, T.M.; Miguel, R.; Bugalho, P.M. Cognitive complaints in Parkinson’s disease patients: From subjective cognitive complaints to dementia and affective disorders. J. Neural Transm. 2019, 126, 1329–1335. [Google Scholar] [CrossRef]
- Chua, C.Y.; Koh, M.R.E.; Chia, N.S.-Y.; Ng, S.Y.-E.; Saffari, S.E.; Wen, M.-C.; Chen, R.Y.-Y.; Choi, X.; Heng, D.L.; Neo, S.X.; et al. Subjective cognitive Complaints in early Parkinson’s disease patients with normal cognition are associated with affective symptoms. Park. Relat. Disord. 2021, 82, 24–28. [Google Scholar] [CrossRef]
- Reynolds, G.O.; Hanna, K.K.; Neargarder, S.; Cronin-Golomb, A. The Relation of anxiety and cognition in Parkinson’s sisease. Neuropsychology 2017, 31, 596–604. [Google Scholar] [CrossRef] [PubMed]
- Verbaan, D.; Marinus, J.; Visser, M.; Rooden, S.M.; Stiggelbout, A.M.; Middelkoop, H.A.; van Hilten, J.J. Cognitive impairment in Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry 2007, 78, 1182. [Google Scholar] [CrossRef] [PubMed]
- Miller, N.; Noble, E.; Jones, D.; Burn, D. Life with communication changes in Parkinson’s disease. Age Ageing 2006, 35, 235–239. [Google Scholar] [CrossRef] [PubMed]
- Ahn, S.; Springer, K.; Gibson, J.S. Social withdrawal in Parkinson’s disease: A scoping review. Geriatr. Nurs. 2022, 48, 258–268. [Google Scholar] [CrossRef]
- Noguchi, T.; Kubo, Y.; Hayashi, T.; Tomiyama, N.; Ochi, A.; Hayashi, H. Social isolation and self-reported cognitive decline among older adults in Japan: A longitudinal study in the COVID-19 pandemic. J. Am. Med. Dir. Assoc. 2021, 22, 1352–1356.e2. [Google Scholar] [CrossRef]
- Brooks, S.K.; Weston, D.; Greenberg, N. Social and psychological impact of the COVID-19 pandemic on people with Parkinson’s disease: A scoping review. Public Health 2021, 199, 77–86. [Google Scholar] [CrossRef]
- McDaniels, B.; Subramanian, I. Social isolation, loneliness and mental health sequelae of the Covid-19 pandemic in Parkinson’s disease. Int. Rev. Neurobiol. 2022, 165, 197–227. [Google Scholar] [CrossRef]
- Olchik, M.R.; Ayres, A.; Ghisi, M.; Schuh, A.F.S.; Rieder, C.R.M. The impact of cognitive performance on quality of life in individuals with Parkinson’s disease. Dement. Neuropsychol. 2016, 10, 303–309. [Google Scholar] [CrossRef]
- Klepac, N.; Trkulja, V.; Relja, M.; Babić, T. Is quality of life in non-demented Parkinson’s disease patients related to cognitive performance? A clinic-based cross-sectional study. Eur. J. Neurol. 2008, 15, 128–133. [Google Scholar] [CrossRef]
- Brown, E.G.; Chahine, L.M.; Goldman, S.M.; Korell, M.; Mann, E.; Kinel, D.R.; Arnedo, V.; Marek, K.L.; Tanner, C.M. The effect of the COVID-19 pandemic on people with Parkinson’s disease. J. Park. Dis. 2020, 10, 1365–1377. [Google Scholar] [CrossRef]
All BOSS-PD (2017–2018) n = 347 | Only BOSS-PD (2017–2018) n = 217 | Matched BOSS-PD + PD-COVID at T1 (2017–2018) n = 123 a | Matched BOSS-PD + PD-COVID at T2 (2021) n = 123 a | |
---|---|---|---|---|
Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | |
Age | 64.8 (8.5) | 65.6 (8.7) | 63.8 (7.9) | 67.2 (7.9) |
(years) | n = 214 | |||
Min. | 40 | 45 | 40 | 44 |
Max. | 91 | 91 | 81 | 84 |
Education | 16.7 (2.6) | 16.7 (2.7) | 16.8 (2.4) | 16.8 (2.4) |
(years) | n = 214 | |||
Min. | 10 | 10 | 10 | 10 |
Max | 21 | 21 | 21 | 21 |
Gender (N) | ||||
Male | 165 | 108 | 54 | 54 |
Female | 180 | 107 | 69 | 69 |
No response | 2 | 2 | 0 | |
PD Duration (years) | 5.4 (4.6) | 5.6 (4.5) | 5.0 (4.8) | 8.1 (4.8) |
All BOSS-PD n = 347 | Only BOSS-PD n = 217 | Matched BOSS-PD + PD-COVID at T1 n = 123 | Matched BOSS-PD + PD-COVID at T2 n = 123 | T1–T2 Mean Change (SE) | Two-Sample Wilcoxon Signed Rank Test Between Matched Participants at T1 and T2 (z-Score) | |
---|---|---|---|---|---|---|
Neuro-QoLsocial a (score range: 8–24) | 34.5 (6.9) | 34.2 (7.1) | 35.4 (6.1) | 33.8 (6.6) | 1.6 (0.6) | 3.6 ** |
Neuro-QoLcog a (score range: 8–24) | 33.5 (6.4) | 32.9 (6.8) | 34.5 (5.6) | 33.0 (6.1) | 1.5 (0.4) | 3.6 ** |
Neuro-QoLfatigue (score range: 8–24) | 17.4 (7.0) | 18.2 (7.1) | 16.1 (6.8) | 16.8 (6.6) | −0.7 (0.5) | 2.0 |
Neuro-QoLwell-being (score range: 9–26) | 36.3 (7.8) | 35.9 (8.1) | 37.1 (7.3) | 36.1 (7.4) | 1 (0.6) | 1.8 |
UPDRS-Inon-motor (score range: 0–28) | 8.0 (4.3) | 8.3 (4.5) | 7.2 (3.8) | 7.6 (3.8) | −0.4 (0.3) | 1.6 |
UPDRS-IImotor (score range: 0–52) | 10.6 (7.5) | 11.3 (8.0) | 9.2 (6.0) | 11.5 (6.8) | −2.3 (0.4) | 9.6 ** |
BDI-II b (score range: 0–63) | 8.6 (6.8) | 9.0 (6.8) | 7.5 (6.5) | 8.0 (6.8) | 0.52 | |
PAS b (score range: 0–48) | 6.6 (6.8) | 7.2 (7.2) | 5.6 (5.8) | 5.5 (6.3) | 0.1 (0.4) | 0.77 |
CIS Total (score range: 9–36) | - | - | - | 16.4 (3.4) | - | - |
T2 Age | Education | T2 PD Duration | Neuro-QoLsocial | Neuro-QoLcog | Neuro-QoLfatigue | Neuro-QoLwell-being | UPDRSnon-motor | UPDRSmotor | BDI-II | PAS | CIS | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
T2 Age | - | |||||||||||
Education | 0.11 | - | ||||||||||
T2 PD Duration | 0.10 | −0.19 | - | |||||||||
Neuro-QoLsocial | 0.02 | 0.01 | −0.07 | - | ||||||||
Neuro-QoLcog | −0.01 | 0.10 | −0.19 * | 0.32 *** | - | |||||||
Neuro-QoLfatigue | −0.02 | −0.05 | 0.07 | −0.26 * | −0.33 ** | - | ||||||
Neuro-QoLwell-being | 0.18 * | −0.05 | −0.06 | 0.22 * | 0.10 | −0.32 *** | - | |||||
UPDRS-Inon-motor | −0.07 | −0.05 | 0.05 | −0.13 | −0.12 | 0.21 * | −0.04 | - | ||||
UPDRS-IImotor | −0.23 ** | −0.14 | 0.15 | −0.32 *** | −0.23 ** | 0.32 *** | −0.14 | 0.36 *** | - | |||
BDI | 0.04 | −0.15 | 0.09 | −0.18 * | −0.44 ** | 0.33 *** | −0.30 ** | 0.09 | 0.28 ** | - | ||
PAS | −0.20 * | −0.10 | −0.03 | −0.28 ** | −0.40 ** | 0.30 *** | −0.29 ** | 0.25 ** | 0.33 *** | 0.43 *** | - | |
T2 CIS | −0.27 ** | −0.10 | 0.18 | 0.02 | 0.06 | 0.03 | 0.11 | −0.01 | 0.15 | 0.09 | −0.03 | - |
Variable | B | SE | β | t |
---|---|---|---|---|
Constant | 2.38 | 0.70 | 3.4 *** | |
UPDRS-IImotor | 0.04 | 0.08 | 0.04 | 0.5 |
BDI-II | −0.212 | 0.07 | −0.27 | 3.1 ** |
PAS | −0.19 | 0.08 | −0.21 | 2.3 ** |
Neuro-QoLsocial | 0.12 | 0.05 | 0.19 | 2.2 * |
Neuro-QoLfatigue | −0.11 | 0.07 | −0.13 | 1.5 |
T2 PD Duration | −0.14 | 0.07 | −0.16 | 2.0 * |
Variable | B | SE | β | t |
---|---|---|---|---|
Constant | 0.18 | 0.68 | 0.3 | |
UPDRS-IImotor | −0.31 | 0.13 | −0.22 | 2.4 * |
PAS | −0.207 | 0.144 | −0.141 | 1.4 |
Neuro-QoLcog | 0.35 | 0.15 | 0.21 | 2.3 * |
Neuro-QoLfatigue | −0.09 | 0.13 | −0.07 | 0.7 |
Neuro-QoLwell-being | 0.13 | 0.09 | 0.13 | 1.4 |
T2 Age | Education | T2 PD Duration | Neuro-QoLsocial | Neuro-QoLcog | Neuro-QoLfatigue | Neuro-QoLwell-being | UPDRSnon-motor | UPDRSmotor | BDI-II | PAS | |
---|---|---|---|---|---|---|---|---|---|---|---|
T2 Age | -- | ||||||||||
Education | 0.01 | -- | |||||||||
T2 PD Duration | 0.15 | −0.12 | -- | ||||||||
Neuro-QoLsocial | −0.05 | −0.16 | 0.14 | -- | |||||||
Neuro-QoLcog | −0.02 | 0.04 | −0.18 | 0.22 | -- | ||||||
Neuro-QoLfatigue | −0.05 | −0.01 | −0.03 | −0.12 | −0.36 ** | -- | |||||
Neuro-QoLwell-being | 0.27 * | −0.09 | −0.02 | 0.08 | 0.04 | −0.24 | -- | ||||
UPDRS-Inon-motor | −0.06 | 0.05 | 0.19 | 0.02 | −0.16 | 0.28 * | 0.04 | -- | |||
UPDRS-IImotor | −0.20 | −0.03 | 0.01 | −0.15 | −0.22 | 0.35 ** | 0.06 | 0.40 ** | -- | ||
BDI-II | 0.13 | −0.07 | 0.04 | −0.11 | −0.51 ** | 0.37 ** | −0.19 | 0.05 | 0.18 | -- | |
PAS | −0.17 | 0.12 | 0.10 | −0.20 | −0.53 ** | 0.40 ** | −0.17 | 0.18 | 0.15 | 0.47 ** | -- |
T2 CIS | −0.32 * | 0.04 | 0.11 | 0.12 | 0.27 * | 0.01 | 0.09 | 0.10 | −0.03 | −0.15 | 0.07 |
T2 Age | Education | T2 PD Duration | Neuro-QoLsocial | Neuro-QoLcog | Neuro-QoLfatigue | Neuro-QoLwell-being | UPDRSnon-motor | UPDRSmotor | BDI-II | PAS | |
---|---|---|---|---|---|---|---|---|---|---|---|
T2 Age | -- | ||||||||||
Education | 0.21 | -- | |||||||||
T2 PD Duration | 0.10 | −0.20 | -- | ||||||||
Neuro-QoLsocial | 0.09 | 0.12 | −0.14 | -- | |||||||
Neuro-QoLcog | −0.01 | 0.16 | −0.19 | 0.42 ** | -- | ||||||
Neuro-QoLfatigue | −0.005 | −0.06 | 0.08 | −0.33 ** | −0.31 * | -- | |||||
Neuro-QoLwell-being | 0.03 | −0.04 | −0.06 | 0.38 ** | 0.17 | −0.42 ** | -- | ||||
UPDRS-Inon-motor | −0.08 | −0.15 | 0.01 | −0.27 * | −0.09 | 0.20 | −0.17 | -- | |||
UPDRS-IImotor | −0.26 * | −0.23 | 0.24 * | −0.48 ** | −0.25 * | 0.32 ** | −0.42 ** | 0.31 ** | -- | ||
BDI-II | −0.09 | −0.22 | 0.09 | −0.23 | −0.33 ** | 0.30 * | −0.46 ** | 0.16 | 0.41 ** | -- | |
PAS | −0.23 | −0.25 * | −0.09 | −0.33 ** | −0.29 * | 0.25 * | −0.44 ** | 0.31 ** | 0.48 ** | 0.40 ** | -- |
T2 CIS | −0.23 | −0.21 | 0.18 | −0.04 | −0.15 | −0.004 | 0.20 | −0.07 | −0.03 | −0.07 | −0.09 |
Neuro-QoLsocial | Neuro-QoLcog | CIS: item1 | CIS: item2 | CIS: item3 | CIS: item4 | CIS: item5 | CIS: item6 | CIS: item7 | CIS: item8 | CIS: item9 | |
---|---|---|---|---|---|---|---|---|---|---|---|
Neuro-QoLsocial | -- | ||||||||||
Neuro-QoLcog | 0.33 * | -- | |||||||||
CIS: item1 | 0.03 | 0.06 | -- | ||||||||
CIS: item2 | −0.09 | 0.06 | 0.25 | -- | |||||||
CIS: item3 | 0.07 | −0.01 | 0.09 | 0.28 * | -- | ||||||
CIS: item4 | 0.05 | 0.08 | 0.16 | 0.18 | 0.21 | -- | |||||
CIS: item5 | 0.27 * | 0.30 * | 0.16 | 0.26 | 0.08 | 0.31 * | -- | ||||
CIS: item6 | −0.05 | 0.01 | 0.30 * | 0.23 | 0.30 * | 0.23 | 0.08 | -- | |||
CIS: item7 | 0.11 | −0.11 | 0.30 * | 0.30 * | 0.24 | 0.02 | 0.12 | 0.36 ** | -- | ||
CIS: item8 | 0.18 | 0.14 | 0.08 | 0.03 | −0.03 | 0.20 | 0.15 | 0.30 * | 0.19 | -- | |
CIS: item9 | 0.27 | 0.42 ** | 0.09 | 0.18 | −0.10 | 0.09 | 0.30 * | 0.02 | 0.17 | 0.34 * | -- |
Neuro-QoLsocial | Neuro-QoLcog | CIS: item1 | CIS: item2 | CIS: item3 | CIS: item4 | CIS: item5 | CIS: item6 | CIS: item7 | CIS: item8 | CIS: item9 | |
---|---|---|---|---|---|---|---|---|---|---|---|
Neuro-QoLsocial | -- | ||||||||||
Neuro-QoLcog | 0.39 ** | -- | |||||||||
CIS: item1 | 0.07 | −0.001 | -- | ||||||||
CIS: item2 | 0.11 | −0.21 | 0.06 | -- | |||||||
CIS: item3 | 0.14 | −0.08 | 0.03 | 0.18 | -- | ||||||
CIS: item4 | 0.13 | 0.04 | 0.10 | 0.06 | 0.26 * | -- | |||||
CIS: item5 | −0.07 | −0.19 | 0.03 | 0.19 | 0.22 | 0.45 ** | -- | ||||
CIS: item6 | 0.04 | −0.03 | 0.17 | 0.03 | 0.12 | 0.17 | 0.06 | -- | |||
CIS: item7 | 0.06 | 0.11 | 0.11 | 0.03 | −0.09 | 0.16 | −0.05 | 0.23 | -- | ||
CIS: item8 | −0.05 | 0.14 | 0.007 | −0.05 | 0.27 * | 0.35 ** | 0.15 | −0.03 | 0.02 | -- | |
CIS: item9 | −0.006 | −0.05 | 0.19 | 0.02 | −0.03 | 0.07 | 0.18 | 0.11 | −0.03 | 0.16 | -- |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Mukadam, N.; Kinger, S.B.; Neargarder, S.; Salazar, R.D.; McDowell, C.P.; Wall, J.; Kaplan, R.I.; Cronin-Golomb, A. Changes in Subjective Cognitive and Social Functioning in Parkinson’s Disease from Before to During the COVID-19 Pandemic. Healthcare 2025, 13, 70. https://doi.org/10.3390/healthcare13010070
Mukadam N, Kinger SB, Neargarder S, Salazar RD, McDowell CP, Wall J, Kaplan RI, Cronin-Golomb A. Changes in Subjective Cognitive and Social Functioning in Parkinson’s Disease from Before to During the COVID-19 Pandemic. Healthcare. 2025; 13(1):70. https://doi.org/10.3390/healthcare13010070
Chicago/Turabian StyleMukadam, Nishaat, Shraddha B. Kinger, Sandy Neargarder, Robert D. Salazar, Celina Pluim McDowell, Juliana Wall, Rini I. Kaplan, and Alice Cronin-Golomb. 2025. "Changes in Subjective Cognitive and Social Functioning in Parkinson’s Disease from Before to During the COVID-19 Pandemic" Healthcare 13, no. 1: 70. https://doi.org/10.3390/healthcare13010070
APA StyleMukadam, N., Kinger, S. B., Neargarder, S., Salazar, R. D., McDowell, C. P., Wall, J., Kaplan, R. I., & Cronin-Golomb, A. (2025). Changes in Subjective Cognitive and Social Functioning in Parkinson’s Disease from Before to During the COVID-19 Pandemic. Healthcare, 13(1), 70. https://doi.org/10.3390/healthcare13010070